Nautilus Biotechnology Stock Investor Sentiment
| NAUT Stock | USD 0.74 0 0.14% |
Slightly above 59% of all Nautilus Biotechnology's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that some traders are interested. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
Nautilus Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Nautilus Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Nautilus Biotechnology's Stock prices. Below is the latest headlines and news related to Nautilus Biotechnology Stock. Current markets are strongly bullish. About 75% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. This information is accessible both publicly - through Nautilus Biotechnology's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Nautilus-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.
Nautilus Largest EPS Surprises
Earnings surprises can significantly impact Nautilus Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-04-29 | 2025-03-31 | -0.15 | -0.13 | 0.02 | 13 | ||
2024-07-30 | 2024-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2023-08-02 | 2023-06-30 | -0.15 | -0.13 | 0.02 | 13 | ||
2021-11-02 | 2021-09-30 | -0.1 | -0.12 | -0.02 | 20 | ||
2025-07-31 | 2025-06-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2022-05-03 | 2022-03-31 | -0.16 | -0.13 | 0.03 | 18 |
There is far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. This information is accessible both publicly - through Nautilus Biotechnology's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Nautilus-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.
Nautilus Biotechnology Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Parag Mallick of 12000 shares of Nautilus Biotechnology at 0.7323 subject to Rule 16b-3 | 05/08/2025 |
2 | Acquisition by Parag Mallick of 1500 shares of Nautilus Biotechnology at 0.7317 subject to Rule 16b-3 | 05/12/2025 |
3 | Insiders continue to buy Nautilus Biotechnology, Inc. and now own 31 percent shares | 05/15/2025 |
4 | Acquisition by Anna Mowry of 15000 shares of Nautilus Biotechnology at 0.7659 subject to Rule 16b-3 | 05/29/2025 |
5 | Acquisition by Akinsanya Karen of 45000 shares of Nautilus Biotechnology at 0.6951 subject to Rule 16b-3 | 06/23/2025 |
6 | Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3 | 06/24/2025 |
7 | Nautilus Biotechnology Leads The Pack In Our Top 3 Penny Stocks | 06/27/2025 |
8 | Nautilus Biotechnology to Announce Second Quarter 2025Financial Results on July 31, 2025 | 07/15/2025 |
9 | LENZ Therapeutics vs. Nautilus Biotechnology Financial Analysis | 07/22/2025 |
10 | How volatile is Nautilus Biotechnology Inc. stock compared to the market - Capitalize on momentum-driven opportunities - jammulinksnews.com | 07/28/2025 |
11 | Nautilus Biotechnology reports Q2 EPS vs last year NAUT | 07/31/2025 |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.